Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Catenins

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gene expression profiling of the L4-stage nematode Caenorhabditis elegans following ethanol exposure.

Bioscience trends·2026

Same author

Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy.

Frontiers in immunology·2026

Same author

Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.

Blood advances·2026

Same author

CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.

Journal of clinical and experimental hematopathology : JCEH·2026

Same author

Myself/God/Nobody: Simple Ways to Begin Discovering the Patient.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2026

Same author

Mitochondrial control of glycerolipid synthesis by a PEP shuttle.

Cell·2026

Search research articles

Related Experiment Video

Updated: Jul 28, 2025

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

E7386 is not a Specific CBP/β-Catenin Antagonist.

Yusuke Higuchi¹, Cu Nguyen¹, Nyam-Osor Chimge¹

¹Department of Cancer Biology and Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

Current Molecular Pharmacology

|May 31, 2023

Summary

E7386 is not a specific CBP/β-catenin antagonist, unlike ICG-001 and C82. This study compared E7386 to established antagonists, finding it lacks specific CBP/β-catenin antagonism.

Keywords:

Antagonism.C82 CBP E7386 ICG-001 β-catenin

More Related Videos

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Experiment Videos

Last Updated: Jul 28, 2025

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract

Published on: June 17, 2014

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Area of Science:

Biochemistry
Molecular Biology
Drug Discovery

Background:

CBP/β-catenin antagonists target diseases of aging by regulating stem cells and metabolism.
ICG-001 and C82 are well-studied specific CBP/β-catenin antagonists.
PRI-724, an earlier antagonist, had limited oral bioavailability.

Purpose of the Study:

To compare the novel, orally available E7386 with specific CBP/β-catenin antagonists ICG-001 and C82.
To investigate the mechanism of action of E7386.
To determine if E7386 is a specific CBP/β-catenin antagonist.

Main Methods:

Utilized validated biochemical and transcriptional assays.
Performed global transcriptional profiling.
Compared three small molecules: ICG-001, C82, and E7386.

Main Results:

E7386 demonstrated significant differences compared to ICG-001 and C82.
Data strongly suggest E7386 does not specifically antagonize CBP/β-catenin.

Conclusions:

E7386 is not a specific CBP/β-catenin antagonist.
Further research is needed to elucidate E7386's mechanism of action.